DPO

Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.

CHICAGO (GenomeWeb) — Seegene this week plans to submit its first molecular diagnostic test for US Food and Drug Administration clearance, an assay for herpes simplex virus I and II that uses the company's TOCE primer technology for multiplexed real-time PCR.

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

Seegene said this week that BioMérieux has licensed its DPO and TOCE technologies to develop multiplexed molecular tests for food safety.

NEW YORK (GenomeWeb News) – Seegene said today that BioMérieux has taken a license to its DPO and TOCE technologies for the development of multiplexed molecular tests for food safety.
Financial terms of the agreement were not disclosed.

Molecular diagnostics and assay technology developer Seegene said this week that it has added yet another multiplex PCR-based chemistry to its portfolio of nucleic acid amplification, detection, and quantification technologies.

Seegene and DuPont Nutrition & Health said today that they have inked an agreement to jointly develop highly multiplexed assays to detect foodborne pathogens by combining Seegene's real-time PCR and melt curve analysis technology with DuPont's benchtop BAX System.

Seegene in the coming week will unveil a new technology that enables highly multiplexed melt curve analysis on existing commercial real-time PCR instruments.

The partnership combines Seegene's Dual Priming Oligo multiplex PCR technology with Akonni's TruArray gel-drop microarray technology.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.